The ABCC1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-mediated gene-disrupted polyclonal population generated in the HeLa cell line, designed to eliminate functional expression of the multidrug resistance protein MRP1. Unlike monoclonal lines, this polyclonal format contains a mixture of edited alleles, minimizing clonal selection bias and better representing heterogeneous drug response phenotypes. The cells serve as a valuable loss-of-function model for investigating ABCC1-dependent transport activity and its role in chemoresistance mechanisms.
The HeLa host cell line originates from a cervical adenocarcinoma (HPV-18 positive) with a highly aneuploid, tumorigenic phenotype, and is extensively utilized in cancer biology and drug development. Endogenous MRP1 expression in HeLa cells provides a physiologically relevant background for studying multidrug resistance in a cervical cancer context, including the interplay between viral oncoproteins and drug efflux pathways.
ABCC1 encodes MRP1, an ATP-binding cassette transporter that functions as an ATP-dependent efflux pump for a broad range of substrates, including glutathione conjugates, glucuronides, and chemotherapeutic agents such as doxorubicin and vincristine. By exporting these compounds, MRP1 reduces intracellular drug accumulation and contributes to multidrug resistance. Transcriptionally, ABCC1 is regulated by NRF2, MYC, TP53, HIF1A, AP-1, PXR, and CAR, with NRF2 acting through antioxidant response elements. MRP1 directly interacts with glutathione and glutathione S-transferases to facilitate xenobiotic elimination and exports endogenous mediators like leukotriene C4 and conjugated bilirubin. Its activity diminishes oxidative stress via glutathione efflux and limits cytotoxicity of anticancer agents, placing MRP1 centrally within ABC transporter networks that also include ABCB1 (P-glycoprotein) and ABCG2 (BCRP).
Disruption of ABCC1 in HeLa cells allows direct examination of MRP1-specific contributions to drug sensitivity, transporter kinetics, and cellular redox balance. This knockout model facilitates dissection of NRF2-regulated detoxification pathways and the functional compensation between MRP1 and other efflux transporters. The polyclonal nature avoids monoclonal artifacts and provides a heterogeneous system that more closely mirrors clinical tumor heterogeneity, making it ideal for screening chemosensitizers and defining MRP1 substrate specificities.
Applications include efflux assays using fluorescent substrates (calcein-AM, doxorubicin), drug sensitivity testing (MTT, resazurin), and molecular characterization via Western blot, RT-qPCR, and co-immunoprecipitation with GSTs. Glutathione quantification and flow cytometry-based multidrug resistance activity assessments further support mechanistic studies. The knockout can be validated by sequencing and functional rescue experiments. For detailed technical information or ordering, please contact Ascent Research.
